UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study

PloS one, 2017-02, Vol.12 (2), p.e0172957-e0172957

2017

Link zum Volltext

Verfügbarkeit prüfen

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4693-4700

2009

Link zum Volltext

Verfügbarkeit prüfen

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)

Journal of the American College of Surgeons, 2017-04, Vol.224 (4), p.688

2017

Link zum Volltext

Verfügbarkeit prüfen

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

NPJ precision oncology, 2023-02, Vol.7 (1), p.18-18, Article 18

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates: Surgical Results From CALGB 40603 (Alliance)

Annals of surgery, 2015-09, Vol.262 (3), p.434-439

2015

Link zum Volltext

Verfügbarkeit prüfen

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

JAMA surgery, 2020-03, Vol.155 (3), p.e195410

2020

Link zum Volltext

Verfügbarkeit prüfen

Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015

Seminars in radiation oncology, 2016, Vol.26 (1), p.59-70

2016

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Role of Platinum Agents in Aggressive Breast Cancers

Current oncology reports, 2015-02, Vol.17 (2), p.3-3, Article 3

Sikov, William M.

2015

Link zum Volltext

Verfügbarkeit prüfen

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

NPJ breast cancer, 2021-11, Vol.7 (1), p.142-142, Article 142

2021

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

British journal of haematology, 2015-05, Vol.169 (3), p.352-355

2015

Link zum Volltext

Verfügbarkeit prüfen

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer

JAMA network open, 2019-04, Vol.2 (4), p.e192561-e192561

2019

Link zum Volltext

Verfügbarkeit prüfen

Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)

Annals of surgical oncology, 2021-10, Vol.28 (11), p.5960-5971

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.297-304

2016

Link zum Volltext

Verfügbarkeit prüfen

Which patients with early-stage triple-negative breast cancer should receive a platinum?

Clinical advances in hematology & oncology, 2017-07, Vol.15 (7), p.510

Sikov, William M

2017

Link zum Volltext

Verfügbarkeit prüfen

A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I

Supportive care in cancer, 2017-11, Vol.25 (11), p.3407-3416

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)

Breast cancer research and treatment, 2016-08, Vol.159 (1), p.109-118

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

BMC cancer, 2016-04, Vol.16 (1), p.274-274, Article 274

2016

Link zum Volltext

Verfügbarkeit prüfen

ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)

Annals of surgical oncology, 2021-12, Vol.28 (Suppl 3), p.436-437

2021

Link zum Volltext

Verfügbarkeit prüfen

Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy

Radiology. Imaging cancer, 2021-03, Vol.3 (2), p.e200134-e200134

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(103)
Buchkapitel
(1)
Texte
(1)

Sprache

Englisch
(105)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(54)
Humans
(49)
Female
(43)
Oncology
(43)
Middle Aged
(32)
Aged
(27)
Adult
(25)
Breast Cancer
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Treatment Outcome
(22)
Chemotherapy
(21)
Male
(18)
Biological And Medical Sciences
(15)
Neoadjuvant Therapy
(15)
Medical Sciences
(14)
Breast Neoplasms - Drug Therapy
(13)
Breast Neoplasms - Pathology
(12)
Neoplasm Staging
(12)
Aged, 80 And Over
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates: Surgical Results From CALGB 40603 (Alliance)

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015

Assessing the Role of Platinum Agents in Aggressive Breast Cancers

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer

Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Which patients with early-stage triple-negative breast cancer should receive a platinum?

A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I

Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)

Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy

Suchergebnisse filtern